Kidney Stones, Chronic Prostatitis & PKD
Caused by Nanobacteria Infection
Great News for Urologists, Nephrologists & Patients
Important New Urology Treatments & Diagnostics

Review by NanoBiotech Reviews, NanoBiotech, LLC
Please send comments to: reviews@nanobiotech.us

BACKGROUND
In a March, 2005 press article, Nanobac Pharmaceuticals, Inc. stated
that its urology researchers have shown a causal relationship between
Nanobacteria infection and urological disorders such as chronic
prostatitis, kidney stones, and polycystic kidney disease (PKD). Until
these very studies, no infection, either viral or bacterial had ever
been shown to be indicated as a cause of these diseases. Because of the
debilitating nature of these urological diseases, and Nanobac
researchers' knowledge that Nanobacteria played a key role in their
development, Nanobac has focused and continues to focus major efforts
in further defining the relationship between Nanobacteria infection and
these diseases, the development of diagnostic tests for nanobacterial
infections in these diseases and the development of therapies to
effectively treat these diseases.
CHRONIC PROSTATITIS
A recent observational study of chronic prostatitis (CP) patients,
conducted by urology's top prostatitis researcher Daniel Shoskes, M.D
(Cleveland Clinic), demonstrated significant improvement in the
symptoms of chronic prostatitis/chronic pelvic pain syndrome for those
patients who used 3 months of Nanobac's patented nanobiotic treatment.
The treated group of fifteen patients had suffered from prostate stones
and longstanding Chronic Pelvic Pain Syndrome (CPPS) that had been
unresponsive to all prior known medical therapies. Nanobac's
nanobiotic treatment is designed to eliminate the stone-forming
Nanobacteria. Shoskes' study found that 80% of the patients with
Chronic Prostatitis had significant improvement in symptoms after only
3 months treatment. Two patients who had been on complete medical
disability have returned to work. The Nanobac nanobiotic treatment
regimen is currently available.
KIDNEY STONES  &  ASTRONAUTS
Kidney stones can be an excruciatingly painful and debilitating, are
known to affect over 20 million Americans and do recur in 50% of
patients within 5 years. Several studies conducted by prominent medical
researchers worldwide have shown Nanobacteria as the causative culprit
in kidney stone formation. Depending on the patient population,
researchers have reported that up to 97% of kidney stones have
Nanobacteria. Since Nanobacteria create calcium deposits (stones) in
tissue and are physically present in the kidney stones, they are
therefore thought to be the initiating core (nidus) of kidney stones.
This year, research by Neva Ciftcioglu, PhD (Director of Nanobacteria
Research at NASA-Houston) and her NASA scientists published a study
showing Nanobacteria infections to grow faster in space flight
simulated conditions (zero gravity) than here on Earth. This finding
explains why Astronauts frequently develop kidney stones and why they
are particularly at risk for kidney stones on long duration missions.
Ciftcioglu's NASA team is working with Nanobac on this application of
nanobiotics and nanobacterial diagnostics as well as other
applications.
continued please.....

POLYCYSTIC KIDNEY DISEASE (PKD)
Polycystic kidney disease (PKD) is a genetic disorder characterized by
the growth of numerous cysts in the kidneys. The cysts are filled with
fluid (think small water balloons). The PKD cysts can slowly replace
much of the mass of the kidneys, the pressure eventually reduces kidney
function and ultimately leads to kidney failure. PKD is the number one
cause for the need of kidney transplants. Research has shown that in
PKD patients up to 100% of kidney cyst fluids and urine were positive
for Nanobacteria. Because Nanobacteria are present in PKD patients,
Nanobac is prepared to provide diagnostic tests for Nanobacteria
infections and their Nanobiotics to treat the infections.
ABOUT NANOBAC PHARMACEUTICALS
Nanobac Pharmaceuticals' mission is to improve people's health
through the detection and eradication of Nanobacteria infections. Their
pioneering research is firmly establishing the pathogenic roles of
Nanobacteria in a broad arena of tissue calcifications, particularly as
found in coronary artery disease, heart disease, heart valve disease,
vascular disease, kidney diseases and cancers. Nanobac has isolated two
biomarkers of nanobacterial infection and has developed multiple
nanobacteria tests. Nanobac has developed diagnostic tests for the
detection of Nanobacteria in blood, serum, urine and spinal fluids and
has received European (EU) approval of its NB2™ ELISA assays that
detect Nanobacterial infections using Antigen and IgG Antibodies to
Nanobacteria. Nanobac is also seeking FDA approval of these diagnostic
tests for use in the United States. Nanobac exclusively holds a series
of US and foreign Patents that cover the diagnostic testing of and
treatment of nanobacterial infections. Nanobac is currently developing
the first FDA approved Nanobiotics for the treatment of Nanobacterial
infections in different disease states. Nanobac currently markets a
patented Nanobiotic treatment and its nanobacterial tests are currently
available to physicians in research.
CONTACT
Information about Nanobac's products & pipeline may be found at
www.nanobaclifesciences.com or directly through your Email at
info@nanobaclifesciences.com
Nanobac Life Sciences, Inc. stock is publicly traded on the OTC
Bulletin Board under the symbol " NNBP " as Nanobac
Pharmaceuticals.  Nanobac Life Sciences, Inc., 2727 W. ML King, Suite
850, Tampa, FL 33607 (813) 264-2241.